Every Form 4 that Cytokinetics Inc. (CYTK) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CYTK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CYTK filings page.
At Cytokinetics, Inc., EVP Research & Development Fady Ibraham Malik exercised 3,500 non-qualified stock options on October 6, 2026, at an exercise price of $7.80 per share, acquiring 3,500 common shares. He sold 3,500 common shares that day at $61.38 per share. The reported transactions were made under a Rule 10b5-1 trading plan.
Cytokinetics, Inc. President & CEO Robert I. Blum exercised 7,500 non-qualified stock options on September 28, 2026, at $10.60 per share, acquiring 7,500 common shares and selling those shares at $65.46 per share the same day. The transactions were reported under a Rule 10b5-1 plan. After the exercise, Blum held 149,245 non-qualified stock options. Separately, the reported holdings include 2,083 shares each held by The Bridget Blum 2003 Irrevocable Trust and The Brittany Blum 2003 Irrevocable Trust; Blum disclaims beneficial ownership of those trust shares.
CYTOKINETICS INC (CYTK) executive Fady Ibraham Malik, EVP Research & Development, reported an option exercise-and-sale transaction in the company’s stock. On September 22, 2026, he exercised a non-qualified stock option for 3,500 shares of common stock at an exercise price of $7.80 per share and acquired the corresponding common shares directly. The filing states that these transactions were made pursuant to a Rule 10b5-1 trading plan. After the option exercise, he held 23,386 shares of common stock directly as reported in the derivative section, and he then sold 3,500 shares of common stock at $68.29 per share on the same date.
CYTOKINETICS INC (CYTK) director Robert E. Landry reported selling 1,000 shares of Common Stock on September 15, 2026 in an open market or private transaction at $72.13 per share. After this sale, he directly holds 8,184 shares of CYTK common stock. The filing affirms use of a Rule 10b5-1 trading plan.
CYTOKINETICS INC (CYTK) reported multiple insider transactions by President and CEO Robert I. Blum and related trusts. On September 14, 2026, he exercised options for 7,500 shares of common stock at $10.60 per share under a pre-arranged Rule 10b5-1 trading plan and sold those 7,500 shares at $73.44 per share the same day under the same plan. The filing also reports charitable gifts and transfers totaling over 190,000 shares, including a transfer of 97,926 shares to The Bridget Blum 2026 Irrevocable Trust, where he is co-trustee and disclaims beneficial ownership. On September 15, 2026, that trust sold 97,926 shares at $69.33 per share, with Blum disclaiming any beneficial interest in the shares sold or proceeds.
CYTOKINETICS INC (CYTK) reports that director Robert E. Landry sold 1,000 shares of common stock on September 11, 2026 in a transaction described as a sale in the open market or a private transaction at $74.66 per share. Following this sale, he directly holds 9,184 shares of Cytokinetics common stock. The transaction is affirmed as having been made under a Rule 10b5-1 trading plan, indicating it was executed according to a pre-established arrangement.
CYTOKINETICS INC (CYTK) reported that executive vice president of research and development Fady Ibraham Malik exercised options for 3,500 shares of common stock on September 8, 2026 at an exercise price of $7.80 per share and received 3,500 shares of common stock. On the same date, he sold 3,500 shares of common stock at $75.46 per share in a reported sale. Following the option exercise, he held 26,886 derivative option-based shares directly. The company indicates these transactions were carried out under a Rule 10b5-1 trading plan.
CYTOKINETICS INC (CYTK) director Lynne B. Parshall reported selling 5,000 shares of common stock on 2026-09-01 in an open market or private transaction at $71.48 per share. After this sale, Parshall holds 10,784 shares of CYTK common stock directly. The filing affirms the transaction was made under a Rule 10b5-1 trading plan.
CYTOKINETICS INC (CYTK) insider Andrew Callos, EVP and Chief Commercial Officer, exercised 10,000 Non-Qualified Stock Options on 2026-08-31 at an exercise price of $23.26 per share, acquiring 10,000 common shares. On the same date, he sold 10,000 common shares at $70.24 per share, leaving 0 options from this grant outstanding. The filing indicates the transactions were made pursuant to a Rule 10b5-1 trading plan.
CYTOKINETICS INC (CYTK) reported that President & CEO Robert I. Blum exercised options and sold shares in a coordinated transaction under a Rule 10b5-1 trading plan. He exercised 7,500 Non-Qualified Stock Options at an exercise price of $10.60 per share, receiving 7,500 common shares, and on the same date sold 7,500 common shares at $70.24 per share. Following the option exercise, he held 164,245 shares of common stock directly, plus indirect holdings of 2,083 shares in each of two irrevocable trusts.
CYTOKINETICS INC (CYTK) executive Fady Ibraham Malik, EVP Research & Development, reported an option exercise-and-sell transaction. On 2026-08-18 he exercised 3,500 non-qualified stock options at an exercise price of $7.80 per share, acquiring 3,500 shares of common stock, and on the same date sold 3,500 common shares at $75.82 per share. Following the option exercise, he held 30,386 options of this grant directly. The transactions were affirmed as made pursuant to a Rule 10b5-1 trading plan.
CYTOKINETICS INC President & CEO Robert I. Blum exercised options for 7,500 shares of common stock at an exercise price of $10.60 per share and on the same date sold 7,500 shares at $76.76 per share, under a Rule 10b5-1 trading plan. Following the option exercise, he held 171,745 options directly, plus 2,083 shares of common stock in each of two irrevocable trusts reported as indirect ownership.
CYTOKINETICS INC EVP and Chief Commercial Officer Andrew Callos exercised 14,000 non-qualified stock options for Common Stock at $23.26 per share and, on the same date, sold 14,000 shares at $79.88 per share under a Rule 10b5-1 trading plan. Following the exercise, he reports 10,000 stock options remaining. The option grant vests over four years, with 25% after one year and the balance vesting monthly over 36 months, subject to continued employment.
Robert I. Blum, President & CEO of Cytokinetics, exercised 7,500 stock options at $10.60 per share into common stock on July 27, 2026 and sold 7,500 shares at $80.87 per share, pursuant to a Rule 10b5-1 trading plan. Following the option exercise, 179,245 options of this type remain directly held. The filing also reports indirect holdings of 2,083 shares in each of The Bridget Blum 2003 Irrevocable Trust and The Brittany Blum 2003 Irrevocable Trust.
CYTOKINETICS INC EVP Research & Development Fady Ibraham Malik exercised 3,500 non-qualified stock options at $7.80 per share on July 21, 2026, receiving 3,500 common shares and selling the same number at $80.59 per share. The transactions, conducted under a Rule 10b5-1 trading plan, left him holding 33,886 non-qualified stock options.
Cytokinetics, Inc. director Nancy Wysenski reported an acquisition of company stock as equity compensation. On July 15, 2026, she received 75 shares of Common Stock as a fully vested grant under the Cytokinetics Equity in lieu of Cash Retainer Program at an indicated value of $82.6200 per share. Following this grant, she directly holds 33,992 shares of Cytokinetics common stock.
WIERENGA WENDELL reported acquisition or exercise transactions in this Form 4 filing.
Cytokinetics Inc. director Wendell Wierenga received a grant of 75 shares of common stock on July 15, 2026, at $82.62 per share under the company’s Equity in lieu of Cash Retainer Program. The shares were fully vested at grant, bringing his direct holdings to 35,563 shares.
Kaye Edward M. MD reported acquisition or exercise transactions in this Form 4 filing.
CYTOKINETICS INC director Edward M. Kaye, MD received a grant of 151 shares of common stock on July 15, 2026 under the Cytokinetics Equity in lieu of Cash Retainer Program. The shares were fully vested at grant, bringing his direct holdings to 10,434 common shares.
HENDERSON JOHN T reported acquisition or exercise transactions in this Form 4 filing.
Cytokinetics Inc director John T. Henderson received a grant of 272 shares of common stock on 2026-07-15 at 82.62 per share under the company’s Equity in lieu of Cash Retainer Program. The shares are fully vested, bringing his direct holdings to 78,360 shares and indirect spouse-held holdings to 83 shares.
Harrington Robert Arthur reported acquisition or exercise transactions in this Form 4 filing.
Cytokinetics director Harrington Robert Arthur received a grant of 151 shares of common stock on July 15, 2026, under the company’s Equity in lieu of Cash Retainer Program. The shares are fully vested at grant, bringing his direct holdings to 21,932 shares.
Daly James M reported acquisition or exercise transactions in this Form 4 filing.
Cytokinetics Inc director James M. Daly received a grant of 151 shares of Common Stock on 2026-07-15 under the company’s Equity in lieu of Cash Retainer Program. The shares are fully vested at grant and increase his directly held position to 3,390 shares.
Cytokinetics Inc President & CEO Robert I. Blum exercised non-qualified stock options for 7,490 shares of common stock at $10.60 per share and, on the same date, sold a total of 7,500 shares at $82.02 per share in open-market transactions, leaving 377,820 shares held directly and 2,083 shares held indirectly by each of two irrevocable trusts.
CYTOKINETICS INC EVP Research & Development Fady Ibraham Malik reported an exercise-and-sale transaction in company stock. He sold 3,500 shares of common stock in an open-market sale at $86.62 per share and exercised options to acquire 3,500 shares at $7.80 per share. Following these transactions, he directly holds 153,902 shares of common stock and 37,386 non-qualified stock options.
Cytokinetics President & CEO Robert I. Blum reported an open-market sale of 7,500 shares of Cytokinetics common stock at $84.92 per share on July 1, 2026. After this sale, he directly holds 377,830 shares of common stock.
In addition to his direct holdings, there are indirect positions of 2,083 shares held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held by The Brittany Blum 2003 Irrevocable Trust. These trust positions are reported as indirect ownership on the Form 4.
CYTOKINETICS INC executive Andrew Callos reported an option exercise paired with a sale of common stock. On July 1, 2026, he exercised options to acquire 15,000 shares of Common Stock at $23.26 per share, then sold 15,000 shares in an open-market transaction at an average price of $85.80 per share. Following these transactions, he directly owns 58,555 shares of Common Stock and holds 24,000 non-qualified stock options with a $23.26 exercise price expiring on March 31, 2031. The stock options referenced vest over four years, with an initial one-year cliff and monthly vesting thereafter, subject to continued employment.
CYTOKINETICS INC EVP and CFO Sung Lee reported an option exercise and related share sale. Lee exercised non-qualified stock options for 1,112 shares of common stock at $48.51 per share, then sold 1,112 shares in an open-market transaction at $87.79 per share.
Following these transactions, Lee directly holds 63,221 shares of common stock. The filing also shows 26,709 non-qualified stock options remaining outstanding with an exercise price of $48.51 per share and an expiration date of May 30, 2034, indicating a continuing equity stake alongside the sale.
Cytokinetics EVP and CFO Sung Lee reported an exercise-and-sell transaction in company stock. On June 24, 2026, Lee exercised stock options to acquire a total of 38,730 shares of Cytokinetics common stock at strike prices of $48.51 and $44.36 per share, then sold 38,730 shares in an open-market sale at an average price of $82.30 per share. Following the sale, Lee directly owned 63,221 shares of Cytokinetics common stock.
CYTOKINETICS INC EVP and CFO Sung Lee reported a mix of option exercises and share sales. On June 29, 2026, Lee exercised options to acquire a total of 3,134 shares of common stock through multiple transactions at exercise prices of $44.36 and $48.51 per share. On the same date, Lee executed an open-market sale of 3,134 shares of common stock at $85.00 per share, effectively converting option-based compensation into cash while shifting exposure from options into owned shares.
CYTOKINETICS INC EVP of Research & Development Fady Ibraham Malik executed an option exercise and sale in company stock. On June 23, 2026, he exercised options to acquire 3,500 shares of common stock at $7.80 per share, then sold 3,500 shares in an open-market transaction at an average price of $79.51 per share. Following these transactions, he directly held 153,902 shares of common stock and 40,886 non-qualified stock options.
Cytokinetics Inc President & CEO Robert I. Blum reported an open-market sale of 7,500 shares of common stock at $70.46 per share. After this transaction, he directly holds 385,330 shares. In addition, 2,083 shares are held indirectly by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares are held indirectly by The Brittany Blum 2003 Irrevocable Trust.
CYTOKINETICS INC EVP Research & Development Fady Ibraham Malik reported an option exercise paired with a share sale. On June 9, 2026, he exercised options to acquire 3,500 shares of common stock at $7.80 per share and sold 3,500 shares in an open-market transaction at $67.98 per share.
Following these transactions, he directly owned 153,902 shares of common stock and held 44,386 non-qualified stock options. The activity reflects converting a portion of stock options into shares and immediately selling an equivalent number of shares for cash while retaining a substantial remaining equity position.
CYTOKINETICS INC director Edward M. Kaye, MD sold shares in the company. He completed an open-market sale of 2,933 shares of Common Stock at a price of $76.09 per share. After this transaction, he directly holds 10,283 shares of Cytokinetics common stock.
CYTOKINETICS INC executive Andrew Callos reported an option exercise and share sale. On 2026-06-01, he exercised non-qualified stock options to acquire 15,000 shares of Common Stock at $23.26 per share, then sold 15,000 shares in an open-market sale at $74.08 per share.
Following these transactions, Callos directly held 58,555 shares of Common Stock. The exercised stock options were part of an award that vests over four years from grant, with 25% vesting after one year and the remainder vesting monthly over the next 36 months, subject to continued employment.
CYTOKINETICS INC director Lynne Parshall sold shares in the company. On June 1, 2026, she executed an open-market sale of 5,000 shares of Common Stock at $74.08 per share. After this transaction, she directly holds 15,784 shares of Cytokinetics common stock.
Cytokinetics Inc. President and CEO Robert I. Blum reported an open-market sale of 7,500 shares of common stock at $77.21 per share. Following this sale, he holds 392,830 shares directly. Separate trust holdings reported as of the same date each hold 2,083 shares indirectly.
CYTOKINETICS INC director Muna Bhanji received new equity compensation. On 2026-05-27, Bhanji was granted 2,851 shares of common stock at no cost, increasing direct holdings to 26,361 shares.
Bhanji was also awarded a non-qualified stock option for 4,301 shares of common stock at an exercise price of $77.15 per share. The option becomes exercisable on 2026-06-28 and expires on 2036-05-26.
CYTOKINETICS INC director James M. Daly received new equity awards in the form of shares and stock options. He was granted 2,851 shares of Common Stock at no cost, increasing his direct holdings to 3,239 shares. He also received a non-qualified stock option covering 4,301 shares of Common Stock at an exercise price of $77.15 per share. This option becomes exercisable starting on June 27, 2026 and expires on May 26, 2036, reflecting routine equity-based director compensation rather than an open-market purchase.
Harrington Robert Arthur reported acquisition or exercise transactions in this Form 4 filing.
Cytokinetics director Robert Arthur Harrington received equity compensation in the form of common stock and stock options. He was granted 2,851 shares of common stock and now holds 21,781 shares directly.
He was also granted 4,301 non-qualified stock options exercisable at $77.15 per share, expiring on May 26, 2036, linked to 4,301 shares of common stock.
CYTOKINETICS INC director John T. Henderson reported new equity awards. He received a grant of 2,851 shares of common stock at no cost, bringing his direct holdings to 78,088 shares. He was also granted a non-qualified stock option for 4,301 shares at an exercise price of $77.1500 per share, exercisable starting on June 27, 2026 and expiring on May 26, 2036. In addition, 83 shares are reported as indirectly owned through his spouse. These are compensation-related awards, not open-market purchases or sales.
CYTOKINETICS INC director Edward M. Kaye, MD received new equity compensation. He was granted 2,851 shares of Common Stock and now directly holds 13,216 shares. He also received a non-qualified stock option for 4,301 shares at an exercise price of $77.15 per share, exercisable beginning on June 27, 2026 and expiring on May 26, 2036.
Cytokinetics director B. Lynne Parshall received new equity awards. On 2026-05-27, she was granted 2,851 shares of Cytokinetics common stock at no cost, increasing her direct holdings to 20,784 shares.
She was also granted a non-qualified stock option for 4,301 shares of common stock at an exercise price of $77.15 per share, expiring on 2036-05-26. These awards are compensation-related grants rather than open-market purchases or sales.
CYTOKINETICS INC director Robert E. Landry reported equity grants. He received 2,851 shares of Common Stock at no cost, increasing his direct holdings to 10,184 shares. He was also granted a non-qualified stock option for 4,301 shares at an exercise price of $77.15, exercisable starting on June 27, 2026 and expiring on May 26, 2036.
Cytokinetics Inc. director Wendell Wierenga reported equity compensation awards. On May 27, 2026, he received 2,851 shares of Common Stock as a grant at no cash cost, increasing his direct holdings to 35,488 shares.
He was also granted a Non-Qualified Stock Option for 4,301 shares of Common Stock at an exercise price of $77.15 per share. This option is scheduled to become exercisable starting June 27, 2026 and expires on May 26, 2036, adding to his long-term incentive position with the company.
Cytokinetics director Nancy Wysenski received new equity awards in the form of common shares and stock options. She was granted 2,851 shares of Common Stock at no purchase price, increasing her directly held stake to 33,917 shares. She also received a Non-Qualified Stock Option covering 4,301 shares of Common Stock with an exercise price of $77.1500 per share, exercisable into the same number of underlying shares and expiring on May 26, 2036. These awards are classified as grants or awards rather than open-market purchases or sales.
Cytokinetics EVP of Research & Development Fady Ibraham Malik exercised stock options and sold shares in Cytokinetics Inc. On May 19, 2026, he exercised options for 3,500 shares of common stock at $7.80 per share and then executed an open-market sale of 3,500 shares at an average price of $75.69 per share. After these transactions, he directly holds 153,902 shares of common stock and 47,886 non-qualified stock options, indicating the sale represents a small portion of his overall equity position.
CYTOKINETICS INC President & CEO Robert I. Blum reported an open-market sale of 7,500 shares of Common Stock at $77.92 per share. After this transaction, he directly holds 400,330 shares. Separate from his direct position, 2,083 shares are held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares are held by The Brittany Blum 2003 Irrevocable Trust as indirect holdings.
Cytokinetics EVP of Research & Development Fady Ibraham Malik exercised stock options and sold the resulting shares. He exercised 3,500 shares of common stock through a non-qualified stock option at $7.80 per share, then completed an open-market sale of 3,500 shares at $77.37 per share on the same date. Following these transactions, he directly held 153,902 shares of Cytokinetics common stock, indicating his overall share count remained broadly stable after the exercise-and-sell sequence.
Cytokinetics director Wendell Wierenga reported an exercise-and-sell transaction in company stock. He exercised a non-qualified stock option for 4,032 shares of Common Stock at $12.40 per share and on the same date sold 4,032 shares in an open-market trade at $75.00 per share. After these transactions, he directly owns 32,637 shares of Cytokinetics Common Stock, and the option covering 4,032 shares has been fully exercised.
CYTOKINETICS INC executive Sung Lee, EVP and Chief Financial Officer, sold shares in an open-market transaction. On May 5, 2026, Lee sold 23,906 shares of Cytokinetics common stock at an average price of $76.87 per share. After this sale, Lee directly owned 63,221 common shares of the company.
Cytokinetics director John T. Henderson reported an option exercise and related share sale. He exercised non-qualified stock options for 20,000 shares of Common Stock at $7.61 per share and, on the same date, sold 20,000 shares in an open-market transaction at $75.97 per share.
After these transactions, he held 75,237 shares of Common Stock directly and 83 shares indirectly through his spouse. The option grant covering 20,000 shares was fully exercised, leaving no remaining balance under that option.